login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
KRONOS BIO INC (KRON) Stock News
NASDAQ:KRON - Nasdaq -
US50107A1043
-
Common Stock
- Currency: USD
0.88
+0.01 (+1.49%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KRON Latest News, Press Relases and Analysis
All
Press Releases
2 months ago - By: Benzinga
- Mentions:
CYCC
RGNX
HSDT
EYEN
...
12 Health Care Stocks Moving In Thursday's Intraday Session
2 months ago - By: Benzinga
- Mentions:
RGC
APDN
SNTI
HSDT
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
2 months ago - By: Halper Sadeh LLC
- Mentions:
AXL
PRA
SWTX
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders
3 months ago - By: Halper Sadeh LLC
- Mentions:
SSBK
RGLS
XAGE
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
3 months ago - By: Brodsky & Smith LLC
- Mentions:
SSBK
RGLS
XAGE
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq
3 months ago - By: Kahn Swick & Foti, LLC
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
3 months ago - By: Halper Sadeh LLC
- Mentions:
DNB
COLB
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders
3 months ago - By: Brodsky & Smith LLC
- Mentions:
RGLS
COEP
PPBI
COLB
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.
3 months ago - By: Ademi & Fruchter LLP
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
3 months ago - By: Halper Sadeh LLC
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
3 months ago - By: Kronos Bio, Inc.
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
3 months ago - By: Kronos Bio, Inc.
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
4 months ago - By: Kronos Bio, Inc.
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
4 months ago - By: Kronos Bio, Inc.
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
8 months ago - By: Kronos Bio, Inc.
Kronos Bio Announces CEO Transition and Reduction in Force
8 months ago - By: Kronos Bio, Inc.
Kronos Bio Announces CEO Transition and Reduction in Force
9 months ago - By: Kronos Bio, Inc.
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
9 months ago - By: Kronos Bio, Inc.
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
9 months ago - By: Kronos Bio, Inc.
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
9 months ago - By: Kronos Bio, Inc.
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
9 months ago - By: Kronos Bio, Inc.
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
9 months ago - By: Kronos Bio, Inc.
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
9 months ago - By: Kronos Bio, Inc.
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
10 months ago - By: Kronos Bio, Inc.
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
10 months ago - By: Kronos Bio, Inc.
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
10 months ago - By: Kronos Bio, Inc.
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
10 months ago - By: Kronos Bio, Inc.
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
Please enable JavaScript to continue using this application.